Biotech M&A Reaches $106 Billion in 2026 Amid Strong Momentum

AI Summary

Global biopharma M&A has reached $106 billion across 201 deals in 2026, positioning it for the strongest year since pre-COVID, according to PitchBook data. If the pace continues, total deal value could exceed $250 billion by year-end. The average deal value has increased to $527.3 million from $365 million in 2025, driven by strategic acquisitions. Major companies are focusing on 'bolt-on' deals in the $1 billion to $5 billion range, with GSK's $2.2 billion acquisition of RAPT Therapeutics exemplifying this trend.